Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Glenmark Pharmaceuticals Income Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Operating Revenue	118,131	115,832	123,049	109,439	106,410
Other Revenue	8,323	723.29	-	-	162.93
Revenue	126,454	116,556	123,049	109,439	106,573
Revenue Growth (YoY)	8.49%	-5.28%	12.44%	2.69%	8.03%
Cost of Revenue	45,789	44,108	45,481	38,470	38,487
Gross Profit	80,665	72,448	77,568	70,970	68,085
Selling, General & Admin	34,465	31,833	29,176	28,103	28,627
Other Operating Expenses	25,694	23,541	25,124	21,271	22,303
Operating Expenses	66,208	61,066	59,168	53,809	55,102
Operating Income	14,457	11,382	18,400	17,160	12,984
Interest Expense	-5,160	-3,490	-2,981	-3,531	-3,773
Interest & Investment Income	61.78	73.52	97.85	29.97	53.76
Currency Exchange Gain (Loss)	-	2,035	880.54	-752.09	1,379
Other Non Operating Income (Expenses)	-	-	688.35	468.65	-
EBT Excluding Unusual Items	9,359	10,000	17,086	13,376	10,644
Gain (Loss) on Sale of Assets	15.3	57.25	-64.64	3.54	-11.73
Legal Settlements	-	-8,011	-	-	-
Other Unusual Items	-9,010	351.99	-2,609	445.45	328.76
Pretax Income	364.95	2,398	14,412	13,825	10,961
Income Tax Expense	18,673	3,294	4,476	4,124	3,201
Earnings From Continuing Operations	-18,309	-895.61	9,936	9,701	7,760
Earnings From Discontinued Operations	3,973	4,670	-	-	-
Net Income to Company	-14,335	3,774	9,936	9,701	7,760
Minority Interest in Earnings	-681.46	-801.55	-519.38	-0.5	-
Net Income	-15,017	2,972	9,417	9,700	7,760
Net Income to Common	-15,017	2,972	9,417	9,700	7,760
Net Income Growth	-	-68.44%	-2.92%	25.01%	-16.11%
Shares Outstanding (Basic)	282	282	282	282	282
Shares Outstanding (Diluted)	282	282	282	282	282
Shares Change (YoY)	0.00%	-	-	-	-0.00%
EPS (Basic)	-53.22	10.53	33.37	34.38	27.50
EPS (Diluted)	-53.22	10.53	33.37	34.38	27.50
EPS Growth	-	-68.43%	-2.93%	25.01%	-16.11%
Free Cash Flow	-11,638	176.29	3,185	3,565	4,610
Free Cash Flow Per Share	-41.24	0.63	11.29	12.63	16.34
Dividend Per Share	2.500	2.500	2.500	2.500	2.500
Dividend Growth	-	-	-	-	25.00%
Gross Margin	63.79%	62.16%	63.04%	64.85%	63.89%
Operating Margin	11.43%	9.77%	14.95%	15.68%	12.18%
Profit Margin	-11.88%	2.55%	7.65%	8.86%	7.28%
Free Cash Flow Margin	-9.20%	0.15%	2.59%	3.26%	4.33%
EBITDA	18,297	14,289	19,124	19,448	14,906
EBITDA Margin	14.47%	12.26%	15.54%	17.77%	13.99%
D&A For EBITDA	3,840	2,907	723.93	2,287	1,922
EBIT	14,457	11,382	18,400	17,160	12,984
EBIT Margin	11.43%	9.77%	14.95%	15.68%	12.18%
Effective Tax Rate	5116.72%	137.34%	31.06%	29.83%	29.20%
Revenue as Reported	126,531	118,721	124,716	109,941	108,006
Advertising Expenses	5,157	5,270	4,349	4,287	5,698

Updated Feb 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.